Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. Company
    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
Delayed Quote. Delayed London Stock Exchange - 09/24 11:39:22 am
1388 GBX   -1.84%
09/24GLAXOSMITHKLINE ( '') (FORM 6 K : GlaxoSmithKline plc (the 'Company') (Form 6-K)
PU
09/24European ADRs Move Lower in Friday Trading
MT
09/24GLAXOSMITHKLINE : UBS sticks Neutral
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo GlaxoSmithKline plc
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Number of employees : 94 066 people.
Sales per Business
20192020Delta
Pharmaceuticals17 554.0052%17 056.0050% -2.84%
Consumer Healthcare8 995.0026.6%10 033.0029.4% +11.54%
Vaccines7 157.0021.2%6 982.0020.5% -2.45%
Corporate and Other Unallocated48.000.1%28.000.1% -41.67%
GBP in Million
Sales per region
20192020Delta
United States13 890.0041.2%14 556.0042.7% +4.79%
Rest of World11 795.0034.9%11 379.0033.4% -3.53%
Europe7 127.0021.1%7 184.0021.1% +0.8%
United Kingdom942.002.8%980.002.9% +4.03%
GBP in Million
Managers
Name Title Age Since
Emma Walmsley Chief Executive Officer & Executive Director 51 2017
Iain Mackay Chief Financial Officer & Executive Director 59 2019
Karenann Terrell Chief Digital & Technology Officer 58 2017
Hal Barron Executive Director & Chief Scientific Officer 57 2018
Jon Ellis VP & Head-Technology Business Development 53 2019
Amy Altshul SVP-Legal, Research & Development - -
Romulo Colindres VP-Global Medical Affairs Lead for Zoster 49 -
Lynn Laverty Elsenhans Independent Non-Executive Director 63 2012
Urs Rohner Independent Non-Executive Director 61 2015
Manvinder Singh Banga Senior Independent Non-Executive Director 65 2016
Members of the board
Name Title Age Since
Jonathan Symonds Non-Executive Chairman 61 2019
Emma Walmsley Chief Executive Officer & Executive Director 51 2017
Lynn Laverty Elsenhans Independent Non-Executive Director 63 2012
Urs Rohner Independent Non-Executive Director 61 2015
Manvinder Singh Banga Senior Independent Non-Executive Director 65 2016
Jesse L. Goodman, Dr. Independent Non-Executive Director 68 2016
Vivienne Cox Independent Non-Executive Director 61 2016
Laurie H. Glimcher, Dr. Independent Non-Executive Director 68 2017
Hal Barron Executive Director & Chief Scientific Officer 57 2018
Iain Mackay Chief Financial Officer & Executive Director 59 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 5,386,937,397 4,968,070,912 92.2% 355,205,950 6.6% 92.2%
Shareholders
NameEquities%
The Vanguard Group, Inc. 151,654,522 3.01%
BlackRock Fund Advisors 131,211,690 2.61%
Norges Bank Investment Management 117,972,000 2.34%
Dodge & Cox 99,377,874 1.98%
Capital Research & Management Co. (Global Investors) 81,077,927 1.61%
BlackRock Advisors (UK) Ltd. 69,356,000 1.38%
Schroder Investment Management Ltd. 67,445,105 1.34%
State Street Global Advisors Ltd. 66,345,263 1.32%
Threadneedle Asset Management Ltd. 57,003,962 1.13%
Silchester International Investors LLP 56,966,000 1.13%
Holdings
NameEquities%Valuation
LYELL IMMUNOPHARMA, INC. (LYEL) 30,253,189 12.6% 477,697,854 USD
VIR BIOTECHNOLOGY, INC. (VIR) 6,626,027 5.07% 341,505,432 USD
GLAXOSMITHKLINE CONSUMER HEALTHCARE PAKISTAN LIMITED (GSKCH) 100,423,259 85.8% 165,681,305 USD
GLAXOSMITHKLINE S.A.E (BIOC) 76,161,378 91.2% 151,788,865 USD
THERAVANCE BIOPHARMA, INC. (TBPH) 9,644,807 13.1% 80,051,898 USD
BICYCLE THERAPEUTICS LIMITED 1,529,561 7.18% 54,605,328 USD
FULCRUM THERAPEUTICS, INC. (FULC) 1,785,714 4.43% 53,035,706 USD
DONG-A SOCIO HOLDINGS CO., LTD. (A000640) 409,693 6.45% 40,635,384 USD
SPERO THERAPEUTICS, INC. (SPRO) 1,740,606 5.41% 33,506,666 USD
ALLERGY THERAPEUTICS PLC (AGY) 10,118,000 1.58% 4,609,154 USD
Markets and indexes
- Main Market
- FTSE 100 / FTSE 350, FTSE All-Share, FTSE Eurotop 100, Low Carbon 100 Europe, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200, Stoxx UK 50
Stock Exchange Codes
- Bloomberg Code :  GSK:LN
- Reuters Code :  GSK.L
- Datastream Code :  GSK
Company contact information
GlaxoSmithKline plc
980 Great West Road
TW8 9GS Brentford, Greater London

Phone : +44 (0)20 8047 5000
Fax : +44 (0)20 8047 7807
web site : http://www.gsk.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of GlaxoSmithKline plc
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
GLAXOSMITHKLINE PLC3.43%94 962
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.20.05%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY37.22%210 037
ABBVIE INC.-0.07%189 211
ASTRAZENECA PLC20.77%187 304
MERCK & CO., INC.-10.01%186 334
NOVARTIS AG-8.00%186 020
BRISTOL-MYERS SQUIBB COMPANY-2.90%133 838
AMGEN INC.-7.09%121 299
SANOFI4.22%120 553
CHUGAI PHARMACEUTICAL CO., LTD.-21.79%63 921
ALLERGAN PLC0.97%63 659
TAKEDA PHARMACEUTICAL COMPANY LIMITED0.43%53 563
BAYER AG-3.45%53 487
DAIICHI SANKYO COMPANY, LIMITED-12.98%53 247
JIANGSU HENGRUI MEDICINE CO., LTD.-46.38%49 081
ASTELLAS PHARMA INC.19.35%31 844
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY50.88%24 932